4-羟基-6-甲基哚吲 | 61545-41-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 4-羟基-6-甲基哚吲
• 英文名称: 4-hydroxy-6-methyl-indole
• 英文别名: 6-Methyl-1H-indol-4-ol
• CAS: 61545-41-3
• 化学式: C₉H₉NO
• mdl: MFCD07781528
• 分子量: 147.177
• InChiKey: RCSZVTPWGUPMNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  36
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319
• 储存条件：
  室温下保存于惰性气体中

反应信息

• 作为反应物：
  描述：

  4-羟基-6-甲基哚吲 在 adenine deaminase 、 Salmonella enterica tryptophan synthase 、 N-terminally hexahistidine-tagged Psilocybe cubensis decarboxylase 、 N-terminally hexahistidine-tagged Psilocybe cubensis kinase 、 N-terminally hexahistidine-tagged Psilocybe cubensis N-methyltransferase 、 S-adenosyl-L-homocysteine nucleosidase 、 5’-三磷酸腺苷 作用下， 以 aq. phosphate buffer 为溶剂， 生成 6-methylpsilocybin
  参考文献：
  名称：

  朝向6-甲基化的Baocystin和Pyilocybin的酶途径。

  摘要：

  介孢菌素及其直接前体baocystin是精神性介孢菌蘑菇的吲哚生物碱。psilocybin作为抗抑郁和焦虑症的治疗选择的药物兴趣目前正在先进的临床试验中进行研究。在这里，我们报告了从4-羟基-6-甲基-1-色氨酸合成6-甲基化的psilocybin和baocystin的生物催化途径，其被Psilocybe cubensis生物合成酶PsiD和PsiK脱羧和磷酸化。PsiM催化N-甲基化。我们进一步介绍了PsiM的计算机计算机结构模型，该模型揭示了一个保守性很强的SAM结合核心以及可能控制底物偏好的外围非保守性元素。

  DOI：

  10.1002/cbic.201900358

文献信息

• Aminopropanol substituted indole compounds and compositions for the
  申请人：Boehringer Mannheim GmbH

  公开号：US04229464A1

  公开（公告）日：1980-10-21

  New aminopropanol compounds of the formula ##STR1## wherein R is lower alkyl, cycloalkyl or alkylthioalkyl, R.sub.1 is hydrogen or lower alkyl, hydroxyalkyl, pivaloyloxyalkyl, alkoxyalkyl, alkoxycarbonyl, carboxyl or --CONR.sub.3 R.sub.4, in which R.sub.3 and R.sub.4 which can be the same or different, represent hydrogen or lower alkyl, and R.sub.2 is lower alkyl, hydroxyalkyl, alkoxyalkyl or pivaloyloxyalkyl or, when R is alkylthioalkyl or R.sub.1 is pivaloyloxyalkyl, R.sub.2 can also be hydrogen and the pharmacologically acceptable salts thereof; are outstandingly effective in the treatment or prophylaxis of cardiac and circulatory diseases.

  新的氨基丙醇化合物的化学式为##STR1## 其中R是较低的烷基，环烷基或烷基硫基烷基，R.sub.1是氢或较低的烷基，羟基烷基，皮瓦酰氧基烷基，烷氧基烷基，烷氧羰基，羧基或--CONR.sub.3 R.sub.4，在其中R.sub.3和R.sub.4可以相同或不同，表示氢或较低的烷基，R.sub.2是较低的烷基，羟基烷基，烷氧基烷基或皮瓦酰氧基烷基，或当R为烷基硫基烷基或R.sub.1为皮瓦酰氧基烷基时，R.sub.2也可以是氢，并且其药理学可接受的盐，在心脏和循环疾病的治疗或预防方面具有卓越的疗效。
• Aminopropanol compounds and compositions for the treatment of cardiac
  申请人：Boehringer Mannheim GmbH

  公开号：US04076829A1

  公开（公告）日：1978-02-28

  New aminopropanol compounds of the formula ##STR1## wherein R is lower alkyl, cycloalkyl or alkylthioalkyl, R.sub.1 is hydrogen or lower alkyl, hydroxyalkyl, pivaloyloxyalkyl, alkoxyalkyl, alkoxycarbonyl, carboxyl or --CONR.sub.3 R.sub.4, in which R.sub.3 and R.sub.4 which can be the same or different, represent hydrogen or lower alkyl, and R.sub.2 is lower alkyl, hydroxyalkyl, alkoxyalkyl or pivaloyloxyalkyl or, when R is alkylthioalkyl or R.sub.1 is pivaloyloxyalkyl, R.sub.2 can also be hydrogen and The pharmacologically acceptable salts thereof; are outstandingly effective in the treatment or prophylaxis of cardiac and circulatory diseases.

  新的氨基丙醇化合物，其化学式为##STR1## 其中R是低碳基，环烷基或烷基硫基，R.sub.1是氢或低碳基，羟基烷基，皮瓦洛酰氧基烷基，烷氧基烷基，烷氧基羰基，羧基或--CONR.sub.3 R.sub.4，其中R.sub.3和R.sub.4可以相同或不同，表示氢或低碳基，而R.sub.2是低碳基，羟基烷基，烷氧基烷基或皮瓦洛酰氧基烷基或者当R是烷基硫基或R.sub.1是皮瓦洛酰氧基烷基时，R.sub.2也可以是氢。以及其药学上可接受的盐；在治疗或预防心脏和循环疾病方面具有卓越的疗效。
• Process for the preparation of indole derivatives
  申请人：Boehringer Manneheim GmbH

  公开号：US04736043A1

  公开（公告）日：1988-04-05

  The present invention provides a process for the preparation of 4-hydroxyindole derivatives of the general formula: ##STR1## in which R.sub.1 is a hydrogen atom or an alkyl radical containing up to 6 carbon atoms and R.sub.2 is a hydrogen atom or an alkyl radical containing up to 6 carbon atoms, wherein a compound of the general formula: ##STR2## in which R.sub.2 has the same meaning as above, is reacted with a compound of the general formula: R.sub.3 --CH.sub.2 --CO--COOR.sub.1 (III) in which R.sub.1 has the same meaning as above and R.sub.3 is a reactive residue, to give a 2-(2-imino-6-oxocyclohexylidene)-propionic acid derivative of the general formula: ##STR3## in which R.sub.1, R.sub.2 and R.sub.3 have the same meanings as above, which is then cyclized in known manner to give a compound of the general formula: ##STR4## in which R.sub.1 and R.sub.2 have the same meaning as above, which is subsequently dehydrated. The present invention also provides new 4-hydroxyindoles of general formula (I'), as well as new 4-Oxo-4,5,6,7-tetrahydroindoles of general formula (IV).

  本发明提供了一种制备4-羟基吲哚衍生物的方法，其通式为：##STR1## 其中R.sub.1是氢原子或含有多达6个碳原子的烷基基团，R.sub.2是氢原子或含有多达6个碳原子的烷基基团，其中通式为：##STR2## 其中R.sub.2具有上述相同的含义，与通式为R.sub.3--CH.sub.2--CO--COOR.sub.1(III)的化合物反应，其中R.sub.1具有上述相同的含义，R.sub.3是反应性残基，以给出通式为：##STR3## 其中R.sub.1，R.sub.2和R.sub.3具有上述相同的含义，然后按照已知的方法环化，以给出通式为：##STR4## 其中R.sub.1和R.sub.2具有上述相同的含义，随后进行脱水。本发明还提供了新的通式为(I')的4-羟基吲哚和新的通式为(IV)的4-氧代-4,5,6,7-四氢吲哚。
• 4-oxo-4,5,6,7-Tetrahydroindole derivatives
  申请人：Boehringer Mannheim GmbH

  公开号：US04824965A1

  公开（公告）日：1989-04-25

  The present invention provides a process for the preparation of 4-hydroxyindole derivatives of the general formula: ##STR1## in which R.sub.1 is a hydrogen atom or an alkyl radical containing up to 6 carbon atoms and R.sub.2 is a hydrogen atom or an alkyl radical containing up to 6 carbon atoms, wherein a compound of the general formula: ##STR2## in which R.sub.2 has the same meaning as above, is reacted with a compound of the general formula: R.sub.3 --CH.sub.2 --CO--COOR.sub.1 (III) in which R.sub.1 has the same meaning as above and R.sub.3 is a reactive residue, to give a 2-(2-imino-6-oxocyclohexylidene)-propionic acid derivative of the general formula: ##STR3## in which R.sub.1, R.sub.2 and R.sub.3 have the same meanings as above, which is then cyclized in known manner to give a compound of the general formula: in which R.sub.1 and R.sub.2 have the same meanings as above, which is subsequently dehydrated. The present invention also provides new 4-hydroxyindoles of the general formula (I'), as well as new 4-oxoindoles of general formula (IV).

  本发明提供了一种制备4-羟基吲哚衍生物的方法，其通式为：##STR1## 其中R.sub.1是氢原子或含有最多6个碳原子的烷基基团，R.sub.2是氢原子或含有最多6个碳原子的烷基基团，其中通式为：##STR2## 其中R.sub.2具有与上述相同的含义，与通式为：R.sub.3 --CH.sub.2 --CO--COOR.sub.1 (III) 的化合物反应，其中R.sub.1具有与上述相同的含义，R.sub.3是反应性残基，以给出通式为：##STR3## 其中R.sub.1，R.sub.2和R.sub.3具有与上述相同的含义，然后以已知的方式环化，以给出通式为：其中R.sub.1和R.sub.2具有与上述相同的含义，然后进行脱水。本发明还提供了新的通式为(I')的4-羟基吲哚和通式为(IV)的新的4-氧代吲哚。
• [EN] SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS<br/>[FR] DÉRIVÉS DE SPIROCYCLOHEXANE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS ANTI-APOPTOTIQUES
  申请人：SERVIER LAB

  公开号：WO2022152705A1

  公开（公告）日：2022-07-21

  Compounds of Formula (I) wherein R1, R3, R11, R12, X, Y1, Y2, Y3, Y4and formula (II) are as defined in the description. Medicaments.

  公式（I）化合物，其中R1、R3、R11、R12、X、Y1、Y2、Y3、Y4和公式（II）如描述中所定义。药物。